vs

Side-by-side financial comparison of Surgery Partners, Inc. (SGRY) and SSR MINING INC. (SSRM). Click either name above to swap in a different company.

Surgery Partners, Inc. is the larger business by last-quarter revenue ($885.0M vs $521.7M, roughly 1.7× SSR MINING INC.). SSR MINING INC. runs the higher net margin — 34.8% vs -1.7%, a 36.5% gap on every dollar of revenue. On growth, SSR MINING INC. posted the faster year-over-year revenue change (61.4% vs 2.4%). SSR MINING INC. produced more free cash flow last quarter ($106.4M vs $90.6M). Over the past eight quarters, SSR MINING INC.'s revenue compounded faster (50.5% CAGR vs 11.1%).

United Surgical Partners International, Inc. (USPI) is an American ambulatory care company based in Dallas, Texas. It was founded by Don Steen in 1998.

SSR Mining Inc., formerly Silver Standard Resources is a Denver-based gold, silver, copper, lead and zinc producer that owns the largest silver mine in Argentina. In addition it engages in exploration activity throughout the Americas and Turkey. In 2020, SSR Mining merged with Alacer Gold. Since the merger, the company has moved headquarters to Denver, Colorado. Rodney P. Antal is now the president and CEO of SSR mining. In February 2021, SSR Mining announced that Alison White would be the ne...

SGRY vs SSRM — Head-to-Head

Bigger by revenue
SGRY
SGRY
1.7× larger
SGRY
$885.0M
$521.7M
SSRM
Growing faster (revenue YoY)
SSRM
SSRM
+59.0% gap
SSRM
61.4%
2.4%
SGRY
Higher net margin
SSRM
SSRM
36.5% more per $
SSRM
34.8%
-1.7%
SGRY
More free cash flow
SSRM
SSRM
$15.8M more FCF
SSRM
$106.4M
$90.6M
SGRY
Faster 2-yr revenue CAGR
SSRM
SSRM
Annualised
SSRM
50.5%
11.1%
SGRY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SGRY
SGRY
SSRM
SSRM
Revenue
$885.0M
$521.7M
Net Profit
$-15.0M
$181.5M
Gross Margin
Operating Margin
12.5%
38.8%
Net Margin
-1.7%
34.8%
Revenue YoY
2.4%
61.4%
Net Profit YoY
86.2%
3166.6%
EPS (diluted)
$-0.11
$0.84

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SGRY
SGRY
SSRM
SSRM
Q4 25
$885.0M
$521.7M
Q3 25
$821.5M
$385.8M
Q2 25
$826.2M
$405.5M
Q1 25
$776.0M
$316.6M
Q4 24
$864.4M
$323.2M
Q3 24
$770.4M
$257.4M
Q2 24
$762.1M
$184.8M
Q1 24
$717.4M
$230.2M
Net Profit
SGRY
SGRY
SSRM
SSRM
Q4 25
$-15.0M
$181.5M
Q3 25
$-22.7M
$65.4M
Q2 25
$-2.5M
$90.1M
Q1 25
$-37.7M
$58.8M
Q4 24
$-108.5M
$5.6M
Q3 24
$-31.7M
$10.6M
Q2 24
$-15.5M
$9.7M
Q1 24
$-12.4M
$-287.1M
Operating Margin
SGRY
SGRY
SSRM
SSRM
Q4 25
12.5%
38.8%
Q3 25
12.9%
21.6%
Q2 25
13.5%
26.9%
Q1 25
8.0%
21.1%
Q4 24
14.7%
10.6%
Q3 24
7.9%
3.5%
Q2 24
11.1%
5.8%
Q1 24
10.6%
-163.5%
Net Margin
SGRY
SGRY
SSRM
SSRM
Q4 25
-1.7%
34.8%
Q3 25
-2.8%
17.0%
Q2 25
-0.3%
22.2%
Q1 25
-4.9%
18.6%
Q4 24
-12.6%
1.7%
Q3 24
-4.1%
4.1%
Q2 24
-2.0%
5.2%
Q1 24
-1.7%
-124.7%
EPS (diluted)
SGRY
SGRY
SSRM
SSRM
Q4 25
$-0.11
$0.84
Q3 25
$-0.18
$0.31
Q2 25
$-0.02
$0.42
Q1 25
$-0.30
$0.28
Q4 24
$-0.86
$0.03
Q3 24
$-0.25
$0.05
Q2 24
$-0.12
$0.05
Q1 24
$-0.10
$-1.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SGRY
SGRY
SSRM
SSRM
Cash + ST InvestmentsLiquidity on hand
$239.9M
$575.6M
Total DebtLower is stronger
$3.6B
Stockholders' EquityBook value
$1.7B
$3.5B
Total Assets
$8.1B
$6.1B
Debt / EquityLower = less leverage
2.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SGRY
SGRY
SSRM
SSRM
Q4 25
$239.9M
$575.6M
Q3 25
$203.4M
$445.4M
Q2 25
$250.1M
$438.5M
Q1 25
$229.3M
$341.3M
Q4 24
$269.5M
$417.3M
Q3 24
$221.8M
$365.8M
Q2 24
$213.5M
$384.4M
Q1 24
$185.2M
$492.0M
Total Debt
SGRY
SGRY
SSRM
SSRM
Q4 25
$3.6B
Q3 25
$3.5B
Q2 25
$3.5B
Q1 25
$3.4B
Q4 24
$3.3B
$228.6M
Q3 24
$3.1B
$228.3M
Q2 24
$3.0B
$228.0M
Q1 24
$2.8B
$228.7M
Stockholders' Equity
SGRY
SGRY
SSRM
SSRM
Q4 25
$1.7B
$3.5B
Q3 25
$1.7B
$3.3B
Q2 25
$1.7B
$3.3B
Q1 25
$1.7B
$3.2B
Q4 24
$1.8B
$3.1B
Q3 24
$1.9B
$3.1B
Q2 24
$2.0B
$3.1B
Q1 24
$2.0B
$3.1B
Total Assets
SGRY
SGRY
SSRM
SSRM
Q4 25
$8.1B
$6.1B
Q3 25
$7.9B
$5.9B
Q2 25
$8.0B
$5.8B
Q1 25
$7.9B
$5.6B
Q4 24
$7.9B
$5.2B
Q3 24
$7.5B
$5.1B
Q2 24
$7.5B
$5.2B
Q1 24
$7.0B
$5.3B
Debt / Equity
SGRY
SGRY
SSRM
SSRM
Q4 25
2.10×
Q3 25
2.00×
Q2 25
1.98×
Q1 25
1.98×
Q4 24
1.83×
0.07×
Q3 24
1.63×
0.07×
Q2 24
1.56×
0.07×
Q1 24
1.42×
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SGRY
SGRY
SSRM
SSRM
Operating Cash FlowLast quarter
$103.4M
$172.1M
Free Cash FlowOCF − Capex
$90.6M
$106.4M
FCF MarginFCF / Revenue
10.2%
20.4%
Capex IntensityCapex / Revenue
1.4%
12.6%
Cash ConversionOCF / Net Profit
0.95×
TTM Free Cash FlowTrailing 4 quarters
$195.6M
$241.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SGRY
SGRY
SSRM
SSRM
Q4 25
$103.4M
$172.1M
Q3 25
$83.6M
$57.2M
Q2 25
$81.3M
$157.8M
Q1 25
$6.0M
$84.8M
Q4 24
$111.4M
$95.0M
Q3 24
$65.2M
$-1.3M
Q2 24
$82.8M
$-78.1M
Q1 24
$40.7M
$24.6M
Free Cash Flow
SGRY
SGRY
SSRM
SSRM
Q4 25
$90.6M
$106.4M
Q3 25
$63.8M
$-2.4M
Q2 25
$57.9M
$98.4M
Q1 25
$-16.7M
$39.3M
Q4 24
$89.1M
$56.4M
Q3 24
$45.0M
$-34.1M
Q2 24
$55.9M
$-116.3M
Q1 24
$19.7M
$-9.4M
FCF Margin
SGRY
SGRY
SSRM
SSRM
Q4 25
10.2%
20.4%
Q3 25
7.8%
-0.6%
Q2 25
7.0%
24.3%
Q1 25
-2.2%
12.4%
Q4 24
10.3%
17.5%
Q3 24
5.8%
-13.2%
Q2 24
7.3%
-62.9%
Q1 24
2.7%
-4.1%
Capex Intensity
SGRY
SGRY
SSRM
SSRM
Q4 25
1.4%
12.6%
Q3 25
2.4%
15.4%
Q2 25
2.8%
14.7%
Q1 25
2.9%
14.4%
Q4 24
2.6%
11.9%
Q3 24
2.6%
12.7%
Q2 24
3.5%
20.7%
Q1 24
2.9%
14.8%
Cash Conversion
SGRY
SGRY
SSRM
SSRM
Q4 25
0.95×
Q3 25
0.87×
Q2 25
1.75×
Q1 25
1.44×
Q4 24
17.10×
Q3 24
-0.13×
Q2 24
-8.06×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SGRY
SGRY

Private Insurance$460.5M52%
Government Revenue$368.6M42%
Other$19.8M2%
Self Pay Revenue$19.6M2%
Other Patient Service Revenue Sources$16.5M2%

SSRM
SSRM

Gold$369.3M71%
Concentrate Sales$124.4M24%
Other$19.1M4%
Lead$9.0M2%

Related Comparisons